Esreboxetine Other names AXS-14; PNU-165442G Routes of administration Oral ATC code Legal status
(2S )-2-[(S )-(2-ethoxyphenoxy)phenyl methyl]morpholine
CAS Number PubChem CID IUPHAR/BPS ChemSpider UNII KEGG CompTox Dashboard (EPA ) Formula C 19 H 23 N O 3 Molar mass 313.397 g·mol−1 3D model (JSmol )
CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
N Key:CBQGYUDMJHNJBX-OALUTQOASA-N
N
N Y (what is this?)
Esreboxetine (developmental code names AXS-14, PNU-165442G ) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1] [2] [3] [4] It is the (S ,S )-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.[1] [5]
However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.[6]
References [ ]
^ a b Bingham M, Napier SJ (2009). Transporters as Targets for Drugs (Topics in Medicinal Chemistry) . Berlin: Springer. ISBN 978-3-540-87911-4 .
^ Rao SG (October 2009). "Current progress in the pharmacological therapy of fibromyalgia". Expert Opinion on Investigational Drugs . 18 (10): 1479–93. doi :10.1517/13543780903203771 . PMID 19732029 . S2CID 12726987 .
^ "Search of esreboxetine" . ClinicalTrials.gov .
^ "Musculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM" .
^ Fish PV, Mackenny M, Bish G, Buxton T, Cave R, Drouard D, et al. (2009). "Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs". Tetrahedron Letters . 50 (4): 389–391. doi :10.1016/j.tetlet.2008.11.025 .
^ Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B (July 2012). "Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial" . Arthritis and Rheumatism . 64 (7): 2387–97. doi :10.1002/art.34390 . PMID 22275142 .
Stimulants
Adamantanes
Adapromine
Amantadine
Bromantane
Memantine
Rimantadine
Adenosine antagonists Alkylamines
Cyclopentamine
Cypenamine
Cyprodenate
Heptaminol
Isometheptene
Levopropylhexedrine
Methylhexaneamine
Octodrine
Propylhexedrine
Tuaminoheptane
Ampakines Arylcyclohexylamines Benzazepines
6-Br-APB
SKF-77434
SKF-81297
SKF-82958
Cathinones Cholinergics Convulsants Eugeroics Oxazolines
4-Methylaminorex
Aminorex
Clominorex
Cyclazodone
Fenozolone
Fluminorex
Pemoline
Thozalinone
Phenethylamines Phenylmorpholines Piperazines
2C-B-BZP
3C-PEP
BZP
CM156
DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
GBR-13119
MeOPP
MBZP
oMPP
Vanoxerine
Piperidines
1-Benzyl-4-(2-(diphenylmethoxy)ethyl)piperidine
2-Benzylpiperidine
2-Methyl-3-phenylpiperidine
3,4-Dichloromethylphenidate
4-Benzylpiperidine
4-Fluoromethylphenidate
4-Methylmethylphenidate
Desoxypipradrol
Difemetorex
Diphenylpyraline
Ethylnaphthidate
Ethylphenidate
Methylnaphthidate
Isopropylphenidate
JZ-IV-10
Methylphenidate (Dexmethylphenidate )
Nocaine
Phacetoperane
Pipradrol
Propylphenidate
SCH-5472
Pyrrolidines Racetams
Oxiracetam
Phenylpiracetam
Phenylpiracetam hydrazide
Tropanes
4-fluorotropacocaine
4'-Fluorococaine
Altropane (IACFT)
Brasofensine
CFT (WIN 35,428)
β-CIT (RTI-55)
Cocaethylene
Cocaine
Dichloropane (RTI-111)
Difluoropine
FE-β-CPPIT
FP-β-CPPIT
Ioflupane (123 I)
Norcocaine
PIT
PTT
RTI-31
RTI-32
RTI-51
RTI-112
RTI-113
RTI-120
RTI-121 (IPCIT)
RTI-126
RTI-150
RTI-177
RTI-229
RTI-336
RTI-354
RTI-371
RTI-386
Salicylmethylecgonine
Tesofensine
Troparil (β-CPT, WIN 35,065-2)
Tropoxane
WF-23
WF-33
Tryptamines Others ATC code : N06B
Analgesics (N02A , N02B )
Opioids
Opiates /opium
Codeine #
Morphine # (+naltrexone )
Opium
Laudanum
Paregoric
Semisynthetic
Acetyldihydrocodeine
Benzylmorphine
Buprenorphine (+naloxone )
Butorphanol
Desomorphine
Diamorphine (heroin)
Dihydrocodeine (+paracetamol )
Dihydromorphine
Etorphine
Ethylmorphine
Hydrocodone (+paracetamol , +ibuprofen , +aspirin )
Hydromorphinol
Hydromorphone
Levorphanol
Metopon
Nalbuphine
Nicocodeine
Nicodicodine
Nicomorphine
Oxycodone (+paracetamol , +aspirin , +ibuprofen , +naloxone , )
Oxymorphone
Papaveretum
Thebacon
Synthetic
Paracetamol -typeNSAIDs
Propionates Oxicams
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Acetates COX-2 inhibitors Fenamates Salicylates Pyrazolones
Aminophenazone ‡
Ampyrone
Metamizole (dipyrone)
Nifenazone
Phenazone
Propyphenazone (+paracetamol/caffeine )
Others
Cannabinoids
Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)
Ion channel modulators
Calcium blockers
Alcohol (ethanol)
Gabapentin
Gabapentin enacarbil
Leconotide
Mirogabalin
Pregabalin
Ziconotide
Sodium blockers
Carbamazepine
Lacosamide
Local anesthetics (e.g., cocaine , lidocaine )
Mexiletine
Nefopam
Tricyclic antidepressants (e.g., amitriptyline # )
Nav 1.7/1.8-selective: DSP-2230 §
Funapide §
PF-05089771 §
Potassium openers
Myorelaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine
Others
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
Monoamine reuptake inhibitors
DAT (DRIs )
NET (NRIs )
Norepinephrine–dopamine reuptake inhibitors: Amineptine
Bupropion
Fencamine
Fencamfamin
Hydroxybupropion
Lefetamine
Levophacetoperane
LR-5182
Manifaxine
Methylphenidate
Nomifensine
O-2172
Radafaxine
Serdexmethylphenidate
Solriamfetol
Tricyclic antidepressants: Amitriptyline
Butriptyline
Cianopramine
Clomipramine
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Melitracen
Nortriptyline
Protriptyline
Trimipramine
Tetracyclic antidepressants: Amoxapine
Maprotiline
Mianserin
Oxaprotiline
Setiptiline
Others: Antihistamines (e.g., brompheniramine , chlorphenamine , pheniramine , tripelennamine )
Antipsychotics (e.g., loxapine , ziprasidone )
Arylcyclohexylamines (e.g., ketamine , phencyclidine )
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol , methadone , pethidine (meperidine) , tapentadol , tramadol , levorphanol )
SERT (SRIs )
Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone
Litoxetine
Lubazodone
LY-393558
Quipazine
SB-649915
TGBA01AD
Trazodone
Vilazodone
Vortioxetine
Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
Bicifadine
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
PPPA
Tofenacin
Venlafaxine
Tricyclic antidepressants: Amitriptyline
Cianopramine
Clomipramine
Cyanodothiepin
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Nortriptyline
Pipofezine
Protriptyline
Others:
Amoxapine
Antihistamines (e.g., brompheniramine , chlorphenamine , dimenhydrinate , diphenhydramine , mepyramine (pyrilamine) , pheniramine , tripelennamine )
Antipsychotics (e.g., loxapine , ziprasidone )
Arylcyclohexylamines (e.g., 3-MeO-PCP , esketamine , ketamine , methoxetamine , phencyclidine )
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene , methadone , pethidine (meperidine) , levorphanol , tapentadol , tramadol )
Roxindole
VMATs
Amiodarone
Amphetamines (e.g., amphetamine , methamphetamine , MDMA )
Bietaserpine
Deserpidine
Deutetrabenazine
Dihydrotetrabenazine
Efavirenz
GBR-12935
Ibogaine
Ketanserin
Lobeline
Reserpine
Rose bengal
Tetrabenazine
Valbenazine
Vanoxerine (GBR-12909)
Others
DAT modulators: Agonist-like: SoRI-9804
; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators ��� Monoamine neurotoxins